Vascular depression: A comprehensive exploration of the definition, mechanisms, and clinical challenges

IF 5.1 2区 医学 Q1 NEUROSCIENCES
Siyuan Wu , Yi Zhang , Yingqiong Lu , Yuqi Yin , Chen Yang , Wenjing Tang , Tao Song , Xi Tao , Qing Wang
{"title":"Vascular depression: A comprehensive exploration of the definition, mechanisms, and clinical challenges","authors":"Siyuan Wu ,&nbsp;Yi Zhang ,&nbsp;Yingqiong Lu ,&nbsp;Yuqi Yin ,&nbsp;Chen Yang ,&nbsp;Wenjing Tang ,&nbsp;Tao Song ,&nbsp;Xi Tao ,&nbsp;Qing Wang","doi":"10.1016/j.nbd.2025.106946","DOIUrl":null,"url":null,"abstract":"<div><div>Vascular depression (VaDep), which was proposed over two decades ago, is a distinct subtype of depression primarily observed in patients with stroke and cerebral small-vessel disease and is characterized by white matter hyperintensities; however, the lack of standardized diagnostic criteria and consensus limits its clinical application. This review explores the pathological conditions and vascular risk factors that may precipitate VaDep, particularly in relation to stroke and cerebral small-vessel disease. VaDep is distinguished by unique pathophysiological mechanisms and treatment responses. We categorize these mechanisms into three groups: 1) macroscopic mechanisms, including vascular aging, cerebral hypoperfusion, blood–brain barrier disruption, and neural circuit dysfunction; 2) microscopic mechanisms, involving the inflammatory response, hypothalamic–pituitary–adrenal axis dysregulation, impaired monoamine synthesis, and mitochondrial dysfunction; and 3) undetermined mechanisms, such as microbiota–gut–brain axis dysbiosis. These insights support VaDep as a distinct depression subtype, differentiating it from late-life depression and major depressive disorder. Treatment is challenging, as patients with VaDep often exhibit resistance to conventional antidepressants. Addressing vascular risk factors and protecting vascular integrity are essential for effective management. Future research should validate these mechanisms and develop novel diagnostic and therapeutic approaches to improve VaDep outcomes.</div></div>","PeriodicalId":19097,"journal":{"name":"Neurobiology of Disease","volume":"211 ","pages":"Article 106946"},"PeriodicalIF":5.1000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurobiology of Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969996125001627","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Vascular depression (VaDep), which was proposed over two decades ago, is a distinct subtype of depression primarily observed in patients with stroke and cerebral small-vessel disease and is characterized by white matter hyperintensities; however, the lack of standardized diagnostic criteria and consensus limits its clinical application. This review explores the pathological conditions and vascular risk factors that may precipitate VaDep, particularly in relation to stroke and cerebral small-vessel disease. VaDep is distinguished by unique pathophysiological mechanisms and treatment responses. We categorize these mechanisms into three groups: 1) macroscopic mechanisms, including vascular aging, cerebral hypoperfusion, blood–brain barrier disruption, and neural circuit dysfunction; 2) microscopic mechanisms, involving the inflammatory response, hypothalamic–pituitary–adrenal axis dysregulation, impaired monoamine synthesis, and mitochondrial dysfunction; and 3) undetermined mechanisms, such as microbiota–gut–brain axis dysbiosis. These insights support VaDep as a distinct depression subtype, differentiating it from late-life depression and major depressive disorder. Treatment is challenging, as patients with VaDep often exhibit resistance to conventional antidepressants. Addressing vascular risk factors and protecting vascular integrity are essential for effective management. Future research should validate these mechanisms and develop novel diagnostic and therapeutic approaches to improve VaDep outcomes.
血管性抑郁:对定义、机制和临床挑战的全面探索
血管性抑郁症(VaDep)是20多年前提出的,是一种独特的抑郁症亚型,主要见于中风和脑血管疾病患者,其特征是白质高强度;然而,缺乏标准化的诊断标准和共识限制了其临床应用。这篇综述探讨了可能导致VaDep的病理条件和血管危险因素,特别是与中风和脑血管疾病有关。VaDep具有独特的病理生理机制和治疗反应。我们将这些机制分为三类:1)宏观机制,包括血管老化、脑灌注不足、血脑屏障破坏和神经回路功能障碍;2)微观机制,包括炎症反应、下丘脑-垂体-肾上腺轴失调、单胺合成受损和线粒体功能障碍;3)未确定的机制,如微生物-肠-脑轴生态失调。这些见解支持VaDep作为一种独特的抑郁症亚型,将其与晚期抑郁症和重度抑郁症区分开来。治疗具有挑战性,因为VaDep患者通常对传统抗抑郁药表现出耐药性。解决血管危险因素和保护血管完整性是有效管理的必要条件。未来的研究应该验证这些机制,并开发新的诊断和治疗方法来改善VaDep的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurobiology of Disease
Neurobiology of Disease 医学-神经科学
CiteScore
11.20
自引率
3.30%
发文量
270
审稿时长
76 days
期刊介绍: Neurobiology of Disease is a major international journal at the interface between basic and clinical neuroscience. The journal provides a forum for the publication of top quality research papers on: molecular and cellular definitions of disease mechanisms, the neural systems and underpinning behavioral disorders, the genetics of inherited neurological and psychiatric diseases, nervous system aging, and findings relevant to the development of new therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信